Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPI-326
- Development stage
- Phase 1
- Lead developer
- EpiBiologics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules
- Administration
- Parenteral
01
Overview
EPI-326 is a mutation-independent, bispecific antibody designed to degrade the epidermal growth factor receptor (EGFR), developed by EpiBiologics. It acts as an antineoplastic immunotherapy targeting EGFR-driven cancers. The drug is classified as a new molecular entity and is currently in preclinical development for cancer indications, including non-small cell lung cancer. Its mechanism of action involves antagonism and degradation of the ErbB family of receptors (specifically EGFR/ErbB1), aiming to overcome resistance mechanisms associated with EGFR mutations[1][2].
- Other names
- Mutation-independent EGFR degrading bispecific antibody
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on EPI-326.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPI-326.